PNXP
Pineapple Express Cannabis Company0.0055
+0.0009+19.6%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
206.59KP/E (TTM)
-Basic EPS (TTM)
-0.02Dividend Yield
0%Recent Filings
8-K
10-Q
Q2 FY2026 results
Pineapple Express Cannabis swung to a $246K operating loss in Q2 FY2026 ended July 31, 2025, from a $4K profit a year earlier, as revenues dried up to zero from $10K while expenses ballooned on $113K management fees and $120K professional costs. YTD through six months, the operating loss hit $431K versus a slim $1K profit last year, with net loss at $643K after $229K interest expense and $47K debt discount amortization dragged down the bottom line—far exceeding operating results due to these non-cash hits. The company closed its March 2025 acquisition of Groovy Company for 5M common shares in exchange for 350M Series A preferred shares of Groovy, recognizing $190K in intellectual property intangibles amortized over 5-17 years, yet cash stayed flat at zero amid $937K operating cash inflow offset by the deal's $747K non-cash outlay. Total debt swelled to $3.7M in default convertible notes plus $1.2M accrued interest, leaving an $8.2M stockholders' deficit. No free cash flow disclosed in the 10-Q. Regulatory uncertainties around PINYA meme tokens pose ongoing risks.
10-Q
Q1 FY2026 results
Pineapple Express Cannabis Company posted no revenue for Q1 FY2026 ended April 30, 2025, down from $1,964 a year earlier, while operating expenses jumped to $184,594 from $5,580, yielding an operating loss of $184,594 versus $3,616. Net loss widened to $659,293 from $3,616, with the gap driven by $474,699 in other expenses including interest, debt discount amortization, and derivative changes. Diluted EPS fell to $(0.03) on 21,857,022 weighted shares, consistent with the net loss figure. The company closed its acquisition of GROOVY Company, Inc. in March 2025 for 5,000,000 common shares in exchange for controlling preferred stock, recognizing $190,000 in net intangible assets, yet cash stayed at zero amid a $8.4M working capital deficit from $3.7M convertible notes (all in default) and $1.1M accrued interest. Free cash flow not disclosed in the 10-Q. Regulatory uncertainties in cannabis and token markets pose ongoing risks.
10-K
FY2025 results
Pineapple Express Cannabis Company posted FY2025 revenue of $16,168, a leap from zero the prior year, but wrote off most as bad debt, leaving slim pickings. Net loss narrowed to $31,153 from $59,497, thanks to lower expenses, though a $14,296 hit from dumping its PCI stake stung. Q4 wrapped with the PCI sale on January 31, slashing regulatory baggage but yielding no cash boost—operations burned $45,030 amid zero cash on hand. No dividends or buybacks; just $45,001 from share sales to tread water. The pivot to blockchain via post-year GROOVY buy hints at tech momentum, yet federal cannabis bans loom as a stubborn drag on any quarterly spark.
8-K
Acquires GROOVY blockchain control
Pineapple Express Cannabis Company completed a share exchange on March 5, 2025, acquiring over 51% voting control of GROOVY Company by swapping 5,000,000 common shares for 350,000,000 Series A Preferred shares. This bolsters Pineapple's cannabis operations with GROOVY's blockchain PaaS, featuring NFT-QR authentication to fight counterfeiting and enhance supply chain transparency. Deal assumes GROOVY's convertible debt, convertible into Pineapple common stock. Board appointments follow a transition period.
IPO
Website
Sector
Industry
CPMD
Cannapharmarx Inc.
0.00-0.00
CRON
Cronos Group Inc. Common Share
3.16+0.11
GPFT
GRAPEFRUIT USA INC.
0.00+0.00
MAJI
Marijuana Inc.
0.05-0.02
NXEN
Nexien BioPharma, Inc.
0.00+0.00
NXGB
NxGen Brands Inc.
0.00-0.00
PLSH
Panacea Life Sciences Holdings,
0.09+0.00
PNPL
Pineapple, Inc.
0.13+0.00
PTIX
Protagenic Therapeutics, Inc.
1.52-0.07
PTPI
Petros Pharmaceuticals, Inc.
0.01-0.00